(E)-4-(4-(hydroxymethyl)phenyl)but-3-en-2-one | 1618091-77-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (E)-4-(4-(hydroxymethyl)phenyl)but-3-en-2-one
• 英文别名: (E)-4-[4-(hydroxymethyl)phenyl]but-3-en-2-one
• CAS: 1618091-77-2
• 化学式: C₁₁H₁₂O₂
• 分子量: 176.215
• InChiKey: WYGLACIOVBFUPQ-NSCUHMNNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  (E)-methyl 4-(3-oxobut-1-en-1-yl)benzoate 在 三氟甲磺酸三甲基硅酯 、 三苯基膦 、 二异丁基氢化铝 、 potassium carbonate 作用下， 以 二氯甲烷 、 正己烷 、 甲醇 为溶剂， 反应 1.5h， 以83%的产率得到(E)-4-(4-(hydroxymethyl)phenyl)but-3-en-2-one
  参考文献：
  名称：

  Selective Transformations of Carbonyl Functions in the Presence of α,β-Unsaturated Ketones: Concise Asymmetric Total Synthesis of Decytospolides A and B

  摘要：

  Enones selectively react with a combination of PPh3 and TMSOTf to produce phosphonium silyl enol ethers, which work as protective groups of enones during the reduction of other carbonyl functions and can be easily deprotected to regenerate parent enones at workup. Furthermore, the first ketone selective alkylations in the presence of enones were also accomplished. This in situ protection method was applied to concise asymmetric total syntheses of decytospolides A and B.

  DOI：

  10.1021/ol501463p

文献信息

• Antibacterial agents
  申请人：Andersen Niels H.

  公开号：US20110172174A1

  公开（公告）日：2011-07-14

  Antibacterial compounds of formula I are provided: As well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of the compounds.

  本发明提供了化学式I的抗菌化合物，包括立体异构体、药学上可接受的盐、酯和前药；包括这些化合物的药物组合物；通过给予这些化合物的途径来治疗细菌感染的方法；以及制备这些化合物的方法。
• ENZYME INHIBITORS
  申请人：Donald Alastair David Graham

  公开号：US20120149736A1

  公开（公告）日：2012-06-14

  Compounds of formula (I), inhibit HDAC activity: wherein A, B and D independently represent ═CH— or ═N—; W is —CH═CH— Or —CH 2 CH 2 —; R 1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intra-cellular carboxylesterase enzymes to a carboxylic acid group; R2 and R3 are selected from the side chains of a natural or non-nat-ural alpha amino acid, provided that neither R2 nor R3 is hydrogen, or R2 and R3, taken together with the carbon to which they are attached, form a 3-6 membered saturated cycloalkyl or heterocyclyl ring; Y is a bond, —C(═O)—, —S(═O)2—, —C(═O)O—, —C(═O)NR′—, —C(═5)—NR′, —C(═NH)NR′ or —S(═O) 2 NR — wherein R′ is hydrogen or optionally substituted C 1 —C 6 alkyl; L 1 is a divalent radical of formula —(Alk 1 ) m ,(Q) n (Alk 2 ) p — wherein m, n, p, Q, Alk 1 and Alk 2 are as defined in the claims; X 1 represents a bond; —C(═O); or —S(═O) 2 —; —NR 4 C(═O)—, —C(═O)NR 4 —,— NR 4 C(═O)NR 5 —, —NR 4 S(═O) 2 —, or —S(═O) 2 NR 4 — wherein R4 and R5 are independently hydrogen or optionally substituted C 1 -C 6 alkyl; and z is 0 or 1.

  化合物的化学式（I），抑制HDAC活性：其中A、B和D分别表示═CH—或═N—; W是—CH═CH—或—CH2CH2—; R1是羧酸基（—COOH）或一个酯基，该酯基可被一个或多个细胞内羧酸酯酶水解成羧酸基; R2和R3是从天然或非天然α氨基酸的侧链中选择的，但R2和R3都不是氢，或R2和R3与它们所连接的碳一起形成3-6个成员的饱和环烷基或杂环基; Y是一个键，—C（═O）—，—S（═O）2—，—C（═O）O—，—C（═O）NR′—，—C（═5）—NR′，—C（═NH）NR′或—S（═O）2NR—，其中R′是氢或可选取代的C1-C6烷基; L1是具有公式—（Alk1）m，（Q）n（Alk2）p的二价基团，其中m、n、p、Q、Alk1和Alk2如权利要求中所定义; X1表示一个键;—C（═O）;或—S（═O）2—;—NR4C（═O）—，—C（═O）NR4—，—NR4C（═O）NR5—，—NR4S（═O）2—或—S（═O）2NR4—其中R4和R5独立地是氢或可选取代的C1-C6烷基; z为0或1。
• THERAPEUTIC CURCUMIN DERIVATIVES
  申请人：STC.UNM

  公开号：US20150011494A1

  公开（公告）日：2015-01-08

  Curcumin analogues and methods are provided for treatment of disease.

  提供了类姜黄素及其方法，用于治疗疾病。
• HUMAN THERAPEUTIC AGENTS
  申请人：Life Plus, LLC

  公开号：US20160106724A1

  公开（公告）日：2016-04-21

  Human therapeutic treatment compositions comprise at least two of a curcumin component, a harmine component, and an isovanillin component, and preferably all three in combination. The agents are effective for the treatment of human conditions, especially human cancers.
• THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF
  申请人：Ions Pharmaceutical S.à r.l.

  公开号：US20170042866A1

  公开（公告）日：2017-02-16

  Human therapeutic treatment compositions comprise at least two of a curcumin component, a harmine component, and an isovanillin component, and preferably all three in combination. The agents are effective for the treatment of human conditions, especially human cancers.